Our pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers (select a program to learn more).
Learn more about our THIO Program
Learn more about our 2nd Generation Programs
Pipeline products are under investigation and have not been proven to be safe or effective. There is no guarantee any product will be approved in the sought-after indication or will meet the developmental milestones set forth above.
*Basket study expected to evaluate: Small Cell Lung Cancer (SCLC), Hepatocellular Carcinoma (HCC), Glioblastoma (GBM), Melanoma, Ovarian, Pancreatic, Breast & Prostate cancers.